78Pt Platinum-Based Drugs

Metallotherapeutic Drugs and Metal-Based Diagnostic Agents: The Use of Metals in Medicine

Volumn , Issue , 2005, Pages 489-506

  Brabec, Viktor ^a   Kasparkova, Jana ^a  

^a INSTITUTE OF BIOPHYSICS   (Czech Republic)

Author keywords

DNA protein ternary cross links; Leaving group of carboplatin; Oxaliplatin; Photoactive Pt(IV) azide complexes; Platinum(IV) complexes; Platinum based drugs; Polynuclear platinum compounds; Trans diamminedichloroplatinum

Indexed keywords

EID: 84889461861     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/0470864052.ch25     Document Type: Chapter

References (74)

1. B. Rosenberg, L. Van Camp, J.E. Trosko and V.H. Mansour, Nature 222, 385-386 (1969)
2. E. Wong and C.M. Giandomenico, Chem. Rev. 99, 2451-2466 (1999)
3. Y.P. Ho, S.C.F. AuYeung and K.K.W. To, Med. Res. Rev. 23, 633-655 (2003)
4. M.S. Highley and A.H. Calvert in: Platinum-Based Drugs in Cancer Therapy, L.R. Kelland and N.P. Farrell (Eds), Humana Press Inc.,Totowa/NJ, pp. 171-194 (2000).
5. J. Lokich, Cancer Invest. 19, 756-760 (2001)
6. P.J. O'Dwyer, J.P. Stevenson and S.W. Johnson, Drugs 59, 19-27 (2000)
7. L.R. Wiseman, J.C. Adkins, G.L. Plosker and K.L. Goa, Drugs Aging 14, 459-475 (1999)
8. F. Levi, G. Metzger, C. Massari and G. Milano, Clin. Pharmacokinetics 38, 1-21 (2000)
9. B. Desoize and C. Madoulet, Crit. Rev. Oncol. Hematol. 42, 317-325 (2002)
10. N.P. Johnson, J.-L. Butour, G. Villani et al.Prog. Clin. Biochem. Med. 10, 1-24 (1989)
11. V. Brabec, Prog. Nucleic Acid Res. Mol. Biol. 71, 1-68 (2002)
12. G. Villani, N.T. Le Gac and J.-S. Hoffmann, in: Cisplatin: Chemistry and Biochemistry of a Leading Anticancer Drug, B. Lippert (Ed.), VHCA, Wiley-CH, Zürich, Weinheim, pp. 135-157 (1999).
13. Y. Jungand and S.J. Lippard, J. Biol. Chem. 278, 52084-52092 (2003)
14. M. Kartalou and J.M. Essigmann, Mutat. Res. 478, 23-43 (2001)
15. V. Brabec and J. Kasparkova, Drug Resist. Updates 5, 147-161 (2002)
16. S.W. Johnson, K.V. Ferry and T.C. Hamilton, Drug Resist. Updates 1, 243-254 (1998)
17. M. Kartalou and J.M. Essigmann, Mutat. Res. 478, 1-21 (2001)
18. A.L. Pinto and S.J. Lippard, Proc. Natl. Acad. Sci. USA 82, 4616-4620 (1985)
19. B. Salles, J.L. Butour, C. Lesca and J.P. Macquet, Biochem. Biophys. Res. Commun. 112, 555-563 (1983)
20. M.A. Fuertes, J. Castilla, C. Alonso and J.M. Perez, Curr. Med. Chem. 10, 257-266 (2003)
21. V.M. Gonzalez, M.A. Fuertes, C. Alonso and J.M. Perez, Mol. Pharmacol. 59, 657-663 (2001)
22. F.A. Blommaert, H.C.M. van Dijk-Knijnenburg, F.J. Dijt et al.Biochemistry 34, 8474-8480 (1995)
23. O. Vrana, V. Brabec and V. Kleinwächter, Anticancer Drug Des. 1, 95-109 (1986)
24. J.M. Woynarowski, W.G. Chapman, C. Napier et al.Mol. Pharmacol. 54, 770-777 (1998)
25. J.M. Woynarowski, S. Faivre, M.C.S. Herzig et al.Mol. Pharmacol. 58, 920-927 (2000)
26. J.T. Reardon, A. Vaisman, S.G. Chaney and A. Sancar, Cancer Res. 59, 3968-3971 (1999)
27. B. Spingler, D.A. Whittington and S.J. Lippard, Inorg. Chem. 40, 5596-5602 (2001)
28. A. Vaisman, S.E. Lim, S.M. Patrick et al.Biochemistry 38, 11026-11039 (1999)
29. K. Kawanishi, Y. Miyagi, J. Yamamoto et al.Cancer Chemother. Pharmacol. 47, 303-308 (2001)
30. N. Farrell, L.R. Kelland, J.D. Roberts and M. Van Beusichem, Cancer Res. 52, 5065-5072 (1992)
31. V. Brabec, V. Kleinwächter, J.L. Butour and N.P. Johnson, Biophys. Chem. 35, 129-141 (1990)
32. V. Brabec and M. Leng, Proc. Natl. Acad. Sci. USA 90, 5345-5349 (1993)
33. M. Leng, A. Schwartz and M.J. Giraud-Panis, in: Platinum-Based Drugs in Cancer Therapy, L.R. Kelland and N.P. Farrell (Eds), Humana Press Inc.,Totowa/NJ, pp. 63-85 (2000).
34. M. Coluccia, F. Nassii, F. Loseto et al.J. Med. Chem. 36, 510-512 (1993)
35. V. Brabec, O. Vrana, O. Novakova et al.Nucleic Acids Res. 24, 336-341 (1996)
36. O. Novakova, J. Kasparkova, J. Malina et al.Nucleic Acids Res. 31, 6450-6460 (2003)
37. G. Natile and M. Coluccia, Coord. Chem. 216, 383-410 (2001)
38. J. Kasparkova, O. Novakova, N. Farrell and V. Brabec, Biochemistry 42, 792-800 (2003)
39. V. Brabec, K. Neplechova, J. Kasparkova and N. Farrell, J. Biol. Inorg. Chem. 5, 364-368 (2000)
40. J. Kasparkova, V. Marini, Y. Najajreh et al.Biochemistry 42, 6321-6332 (2003)
41. J. Kasparkova, O. Novakova, V. Marini et al.J. Biol. Chem. 278, 47516-47525 (2003)
42. J.M. Perez, E.I. Montero, A.M. Gonzalez et al.J. Med. Chem. 43, 2411-2418 (2000)
43. E.I. Montero, S. Diaz, A.M. Gonzalez-Vadillo et al.J. Med. Chem. 42, 4264-4268 (1999)
44. N. Farrell, in: Platinum-Based Drugs in Cancer Therapy, L.R. Kelland and N.P. Farrell (Eds), Humana Press Inc.,Totowa/NJ, pp. 321-338 (2000).
45. V. Brabec, J. Kasparkova, O. Vrana et al.Biochemistry 38, 6781-6790 (1999)
46. J. Kasparkova, J. Zehnulova, N. Farrell and V. Brabec, J. Biol. Chem. 277, 48076-48086 (2002)
47. J. Zehnulova, J. Kasparkova, N. Farrell and V. Brabec, J. Biol. Chem. 276, 22191-22199 (2001)
48. E. Fokkema, H.J.M. Groen, M.N. Helder et al.Biochem. Pharmacol. 63, 1989-1996 (2002)
49. K.J. Mellish, C.F.J. Barnard, B.A. Murrer and L.R. Kelland, Int. J. Cancer 62, 717-723 (1995)
50. L.R. Kelland, in: Platinum-Based Drugs in Cancer Therapy, L.R. Kelland and N.P. Farrell (Eds), Humana Press Inc.,Totowa/NJ, pp. 299-319 (2000).
51. P. Muller, B. Schroder, J.A. Parkinson et al.Angew. Chem. Int. Ed. 42, 335-339 (2003)
52. J. Kasparkova, F.S. Mackay, V. Brabec and P.J. Sadler, J. Biol. Inorg. Chem. 8, 741-745 (2003)
53. W.I. Sundquist and S.J. Lippard, Coord. Chem. Rev. 100, 293-322 (1990)
54. M. Leng and V. Brabec, in: DNA Adducts: Identification and Biological Significance, K. Hemminki, A. Dipple, D.E.G. Shuker, F.F. Kadlubar, D. Segerbäck and H. Bartsch (Eds), International Agency for Research on Cancer, Lyon, pp. 339-348 (1994).
55. B.E. Bowler, L.S. Hollis and S.J. Lippard, J. Am. Chem. Soc. 106, 6102-6104 (1984)
56. M. Lee, J.E. Simpson, A.J. Burns et al.Med. Chem. Res. 6, 365-371 (1996)
57. H. Loskotova and V. Brabec, Eur. J. Biochem. 266, 392-402 (1999)
58. H. Kostrhunova and V. Brabec, Biochemistry 39, 12639-12649 (2000)
59. A.A. Bogdanov, C. Martin, A.V. Bogdanova et al.Bioconjug. Chem. 7, 144-149 (1996)
60. Anon.,Expert Opin. Ther. Patents 9, 661-662 (May 1999).
61. M. Bouma, B. Nuijen, D.R. Stewart et al.Anticancer Drugs 13, 915-924 (2002)
62. I. Han, A.R. Khokhar and R. PerezSoler, Cancer Chemother. Pharmacol. 39, 17-24 (1996)
63. A. Mori, S.P. Wu, I. Han et al.Cancer Chemother. Pharmacol. 37, 435-444 (1996)
64. M.S. Newman, G.T. Colbern, P.K. Working et al.Cancer Chemother. Pharmacol. 43, 1-7 (1999)
65. T. Boulikas and M. Vougiouka, Oncol. Rep. 10, 1663-1682 (2003)
66. K.N.J. Burger, R.W.H.M. Staffhorst, H.C. deVijlder et al.Nat. Med. 8, 81-84 (2002)
67. R.C. Taylor and S.G. Ward, in: Lectures in Bioinorganic Chemistry, M. Nicolini and L. Sindellari (Eds), Raven Press, New York, pp. 63-90 (1991).
68. M. Coluccia, A. Boccarelli, C. Cermelli et al.Metal-Based Drugs 2, 249-256 (1995)
69. N.A. Jones, J. Turner, A.J. McIlwrath et al.Mol. Pharmacol. 53, 819-826 (1998)
70. M. Hussain, U. Vaishampayan, W. Du et al.J. Clin. Oncol. 19, 2527-2533 (2001)
71. A. Vasuratna, A.P. Kudelka, C.L. Edwards et al.Anticancer Drugs 9, 283-285 (1998)
72. R.P. Perez, Eur. J. Cancer 34, 1535-1542 (1998)
73. G. Giaccone, Drugs 59, U4-U5 (2000).
74. M. Fujita, T. Fujita, T. Kodama et al.,Int. J. Oncol. 17, 393-397 (2000)